Jutia Group | What's Behind AbbVie's Rocking Q3 Earnings Motley Fool AbbVie's partnership with Biogen Idec (NASDAQ: BIIB ) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that ... AbbVie Inc (ABBV): AbbVie's CEO Discusses Q3 2013 Results - Earnings Call ... AbbVie Reports Third-Quarter 2013 Financial Results |
